فهرست نشریات علمی دسترسی آزاد ایران

Background and Objectives: New cancer therapies based on Escherichia coli (E. coli) have gained significant interest recently. E. coli with genetically modified genes were investigated in this study for their potential to treat cancers.   Methods: The present systematic review was conducted to gather relevant literature on E. coli-based cancer therapies. The current study searched several databases for preclinical studies and early-phase clinical trials. Those studies included in-vitro and in-vivo evaluations of genetically engineered E. coli used for cancer therapy. Furthermore, the current study evaluated the potential of E. coli-based therapy to treat cancer in combination with other therapies and using a personalized approach.   Results: After meticulously reviewing 13,064 publications, 301 studies were included for quantitative analysis, following a screening process, including 44 articles. Live tumor-targeting bacteria have the potential to revolutionize cancer therapeutics, according to the review. Despite the challenges associated with conventional cancer treatments, E. coli offers an alternative strategy that can accumulate and increase within tumors. A variety of anticancer agents can be carried by E. coli via genetic manipulation and synthetic bioengineering, making them ideal carriers for tailored therapeutic approaches. Researchers found they could be used as a monotherapy or combination therapy, presenting a multifaceted solution for enhanced clinical outcomes. Several clinical trials with E. coli targeting tumors are underway, demonstrating that theoretical promise has been translated into practical application.   Conclusion: To conclude, live tumor-targeting bacteria may be able to address the limitations of existing cancer treatments. The selectivity of their antitumor immune responses, programmability, and ability to induce antitumor immune responses indicate a significant advancement. Despite these challenges, ongoing clinical trials suggest a tangible shift in how E. coli can be integrated into cancer treatment regimens. More research and development are needed to utilize these new targeted anticancer strategies to their full potential.